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Pseudo arylsulfatase A deficiency, an asymptomatic condition, and metachromatic leukodystrophy, a severe 
neurodegenerative dis ase, are both associated with profound reductions of arylsulfatase A activity in man. 
We now report hat with metabolic labelling, cultured pseudo deficient cells synthesized about 20% of the 
normal amount of arylsulfatase A at a reduced rate of apparent synthesis and increased rate of degradation. 
However, in the presence of ammonium chloride which stimulated secretion of lysosomal enzymes, these 
cells synthesized about 80% of the normal amount of enzyme protein. Hence, the defect in pseudo arylsulfat- 
ase A deficiency is associated with labile arylsulfatase A molecules which can be stabilized if they are di- 
verted from intracellular storage. 
Lysosomal enzyme; Ammonium chloride; Lipidosis; Metachromatic leukodystrophy 
1. INTRODUCTION 
Pseudo arylsulfatase A deficiency (PD) and 
metachromatic leukodystrophy (MLD) are 
autosomal-recessive conditions in man associated 
with profound reduction in the activity of the 
lysosomal enzyme arylsulfatase A (ARA, EC 
3.1.6.1) [1-3]. Although both conditions are 
associated with allelic mutations of the same gene 
coding for ARA [4], clinically, MLD presents as a 
severe neurodegenerative disorder whereas PD is a 
benign condition. Cultured fibroblasts from MLD 
patients either did not produce cross-reacting- 
material to ARA [5] or ARA that was normal in 
size but highly unstable [6]. Those from PD pa- 
tients produced ARA that was reduced in quantity 
and in size by about 3 kDa when compared to nor- 
mal [5,6]. We now report abnormalities in the 
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biosynthesis of ARA by PD cells and how they 
may be partially reversed under appropriate x- 
perimental conditions. 
2. MATERIALS AND METHODS 
2.1. Tissue culture 
Fibroblasts from 3 normal controls (Ag, A25, 
Sellers) were established from skin biopsies and 
those from patients with PD were supplied by Dr 
H. Kihara, UCLA (578) and Dr E. Kolodny, 
Eunice Kennedy Shriver Center for Mental Retar- 
dation, Inc. (4835, 3475). They were maintained 
under the usual culture conditions [4]. For 
metabolic labelling, each 25 cm 2 flask was seeded 
with 1 x 105 cells. Media were changed once a 
week. After 15-18 days the cells were incubated 
for 1 h in leucine-free Waymouth medium MAB 
87/3 (KC Biological, KS) and then pulsed with 
200/zCi per flask of [4,5-3Hlleucine (NEN, 
Lachine, Quebec) in 3 ml Waymouth medium. For 
chase experiments, the radioactive medium was 
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removed after the pulse, and the cells washed twice 
with 5 ml medium before incubation with 
Waymouth medium containing 5/zg/ml of leucine 
for the chase periods. In experiments with am- 
monium chloride, the medium was supplemented 
with 10 mM NH4CI [7]. 
2.2. Preparation of cell extract and medium 
The cells in each flask were washed twice with 
5 ml phosphate-buffered saline and extracted with 
500/zl of 1070 Nonidet P-40 (Sigma, St. Louis) in 
Tris-buffered saline, pH 7.4. Protein was deter- 
mined according to Bradford [21]. 25/zl leupeptin 
(2 mg/ml,  Boehringer Mannheim, Quebec) were 
added to the extract. From the culture medium, 
protein was precipitated with 75°70 saturation of 
ammonium sulfate [7], dissolved in 200/zl of 
0.01 M Tris-HCl, pH 7.4, containing 0.15 M NaCI 
and 0.02°70 NAN3, desalted with Sephadex G-50 
(Pharmacia, Dorval, Quebec) and leupeptin was 
added as for the cell extract. 
2.3. Immunoprecipitation, electrophoresis and 
fluorography 
The immunoprecipitation [6], solubilization [8] 
and electrophoresis [9] were performed as de- 
scribed. The anti-ARA antiserum was kindly sup- 
plied by Drs G. Bach and E. Neufeld [6]. The 
radioactive bands were detected by fluorography 
and quantitated with a Bio-Rad 620 densitometer 
and 3392A integrator (Bio-Rad, Mississauga, On- 
tario). Each band was scanned three times and the 
mean area under the peak was related to radioac- 
tivity standards incorporated into each 
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Fig.l, (A) Synthesis of ARA by normal (Ag) and PD (578) fibroblasts. Cells were pulsed with 200/zCi [3H]leucine per 
flask. Following extraction with Tris-buffered saline, pH 7.4, containing 1°70 Nonidet P-40, fibronectin was 
immunoprecipitated with 5/zl rabbit anti-human fibronectin antiserum. ARA was isolated by immunoprecipitation with 
2/zl goat anti-ARA antiserum overnight at 4°C. Immunoprecipitates were analyzed by SDS-polyacrylamide 
electrophoresis on 10070 gels at 35 mA for 300 min. The radioactive peptide was quantified by densitometry. Each point 
is the mean of 4 independent experiments with SD of less than 10070. (B) Degradation of ARA in normal and PD 
fibroblasts. Following a 12 h pulse, fibroblasts were chased for 12-48 h. ARA levels were estimated as above. Each 
point is the mean of 3 independent experiments with SD of less than 10070. Molecular mass was estimated by comparison 
with radioactive standards. 
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fluorograph. The linear range of response between 
radioactivity and area under the peak was from 
250 to 1910 cpm. 
3. RESULTS 
The results reported here were obtained for the 
normal cell line, Ag and PD the cell line, 578. 
Similar results (not shown) were obtained with A25 
and Sellers (normal) and 4835 and 3475 (PD). 
The biosynthesis of ARA was followed by pulse- 
chase experiments as shown in fig.1. PD and nor- 
mal cells showed maximal incorporation of 
radioactivity into ARA by 12 h. However, their 
apparent initial rates of synthesis were drastically 
different. For example, after pulsing for 6 h, PD 
cells achieved only 50% of maximal labelling while 
normal cells had incorporated 90°7o f the maximal 
radioactivity already. In addition, after 12 h of 
pulse, the level of labelled ARA was about 
4000 cpm/mg protein for normal fibroblasts, 
while that for PD fibroblasts was only about 
1000 cpm/mg (fig.lA). During the course of this 
labelling, normal cells synthesized a major ARA 
species of 59 kDa and a very minor one of 
54-55 kDa while PD cells synthesized only a single 
detectable species of ARA of 56 kDa. 
Chase experiments demonstrated that the ap- 
parent rates of degradation of ARA between or- 
mal and PD cells were also markedly different 
(fig.lB). A 12 h pulse followed with a 12 h chase 
showed no loss of radioactive ARA in normal cells 
while 30O7o f the ARA in the PD cell had already 
been degraded. The apparent half-life of the 
radioactive ARA was estimated to be 33 h in the 
PD cells whereas in normal cells only 12O7o f the 
labelled ARA was degraded in the same period. 
Neither cell line showed any change in molecular 
mass of ARA subunits during the chase period. 
When the biosynthesis of ARA was followed 
with pulse experiments but in the presence of 
NH4C1, the PD cells demonstrated an unexpectedly 
high level of synthesis when compared to the nor- 
mal (fig.2). The apparent rates of synthesis of the 
intracellular ARA in both normal and PD cells 
were linear in the first 6 h of pulse. The PD cells 
accumulate about 600 cpm/mg protein compared 
to about 1200 cpm/mg protein in normal cells. By 
12 h of pulsing, the ARA in PD cells had again 
achieved maximal incorporation in the cell at 
about 850 cpm/mg protein, compared to about 
1700 cpm/mg protein in the normal cells (fig.2A). 
This represented 50% of normal level instead of 
the 25% in the absence of NH4C1. 
When the secreted form of ARA was followed in 
PD cells, the level of biosynthesis in the presence 
of NH4C1 was even more elevated, surpassing that 
of the normal (fig.2B). In normal cells, secreted 
ARA reached the maximal plateau of incorpora- 
tion at 1700 cpm/mg protein from 9 to 18 h of 
pulse. In PD cells, incorporation continued to in- 
crease and approached the maximum only by 15 h 
of pulsing. Even at 12 h of pulsing, the level of 
radioactivity of ARA in the PD media reached 
about 2000 cpm/mg protein, surpassing that of the 
normal by about 200/o. I f  NHnCI was omitted from 
the media, neither cell type secreted detectable 
levels of labelled ARA (not shown). 
With normal cells, the presence or absence of 
NH4C1 in the medium did not alter the molecular 
masses of either the intracellular or secreted ARA 
subunits (figs IA, 2A or 2B). However, with PD 
cells, in the presence of NHaCI, both the in- 
tracellular and secreted ARA subunits were slightly 
larger, i.e. 57 kDa in fig.2, compared to 56 kDa in 
fig. 1. 
4. DISCUSSION 
The present findings showed that the low level of 
ARA in PD fibroblasts observed previously [5,6] 
was the result of increased egradation. The ap- 
parent initial rate of synthesis of ARA was also 
reduced by 10-fold in PD fibroblasts, i.e. 60 cpm 
ARA/mg protein per h as compared with 600 cpm 
ARA/mg protein per h in normal fibroblasts 
(fig.lA) or by 3-fold if NH4CI, an amine that in- 
creases intralysosomal pH and stimulates ecretion 
of lysosomal enzymes [10], was present (fig.2). 
However, the earliest pulse time was 4 h (fig.2) 
when the newly synthesized ARA may have been 
modified or partially degraded already during its 
passage through prelysosomal compartments. 
Therefore, the reduction in the apparent rate of 
synthesis may not reflect the true reduction in the 
initial rate of synthesis. However, it is very clear 
that the ARA in PD cells was considerably more 
labile, with an apparent half-life of one-ninth that 
of normal enzyme as calculated from fig.lB and 
unpublished ata on chase up to 96 h. 
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Fig.2. Effect of NI-~CI on synthesis and secretion of ARA in normal (Ag) and PD (578) fibroblasts. Experiments were 
performed as described for fig.1 except hat the pulse medium was supplemented with NH4C1 (10 raM). The pulse 
medium was removed and treated as outlined in section 2. (A) Intracellular ARA was determined as described for 
fig. IA. Each point is the mean of 3 independent experiments with SD of less than 10°70. (B) The media were concentrated 
with (NH4)2SO4, desalted and immunoprecipitated as escribed above. Electrophoresis was for 330 min at 35 mA. Each 
point is the mean of 3 independent experiments with SD of less than 10°70. 
Residual amounts of ARA protein with in- 
creased lability were also observed among some 
MLD cells [11]. This raised the question of why the 
two forms of ARA deficiencies result in such dif- 
ferent clinical manifestations, particularly when 
previous complementation studies showed that PD 
and MLD were due to allelic mutations of the same 
structural gene for ARA [4]. A possible explana- 
tion is the different degrees of instability in the two 
mutants. When the newly synthesized ARA in PD 
cells was diverted to the secretory pathway by 
NHaCI, and hence protected from the rapid in- 
tracellular degradation (fig.lB), the extracellular 
pool of ARA rose to above normal levels (fig.2B). 
In contrast, under similar conditions, MLD cells 
accumulated only 15-46070 of the normal ex- 
tracellular level of ARA molecules [11]. In addi- 
tion to the relatively greater stability of the mutant 
ARA molecules in PD, the 5-10070 of residual 
ARA activity in PD cells demonstrated catalytic 
activity towards both artificial [12] and natural 
substrates for ARA [13]. In contrast, the residual 
activity in MLD cells did not possess imilar activi- 
ty. Therefore, the increased stability and authentic 
ARA activity in PD may have contributed towards 
the dramatic difference in the clinical outcomes of 
the two conditions. 
Similar pseudo-deficiency onditions for several 
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lysosomal storage diseases have been reported 
[14-17]. It is of concern that some of these pa- 
tients may eventually develop mild lower neuron 
dysfunction [18,19]. The possibility of similar 
neurological dysfunction developing in the PD pa- 
tients cannot be ruled out. The use of protease in- 
hibitors to elevate ARA levels in fibroblasts has 
produced varying results. Herz and Bach [20] 
found no increase in ARA enzyme activity in PD 
cells, whereas Von Figura et al. [11] showed partial 
restoration of ARA enzyme protein and activity in 
MLD cells when incubated with thiol proteinase in- 
hibitors. Thus, the therapeutic use of protease in- 
hibitors to increase ARA levels in PD or other 
lysosomal enzymes in their respective pseudo defi- 
ciencies should be further investigated. 
In conclusion, our results demonstrate that in 
cultured fibroblasts from PD patients, the reduced 
ARA activity is associated with a labile ARA pro- 
tein which showed an increased rate of degradation 
in the lysosomes. However, near normal levels of 
ARA can be restored in vitro by diverting the en- 
zyme from intracellular storage with NHaC1- 
induced secretion. 
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